• +1-646-491-9876
    • +91-20-67278686

    Search

    Alopecia - Pipeline Review, H1 2015

    Alopecia - Pipeline Review, H1 2015

    • Report Code ID: RW0001172411
    • Category Pharmaceuticals
    • No. of Pages 68
    • Publication Month Jan-15
    • Publisher Name Global Markets Direct
    Alopecia-Pipeline Review, H1 2015

    Summary

    Publisher's, 'Alopecia-Pipeline Review, H1 2015', provides an overview of the Alopecia's therapeutic pipeline.

    This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

    The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

    Scope

    - The report provides a snapshot of the global therapeutic landscape of Alopecia
    - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in the therapeutics development for Alopecia and enlists all their major and minor projects
    - The report summarizes all the dormant and discontinued pipeline projects
    - A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - A detailed assessment of monotherapy and combination therapy pipeline projects
    - Coverage of the Alopecia pipeline on the basis of target, MoA, route of administration and molecule type
    - Latest news and deals relating related to pipeline products

    Reasons to buy

    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Identify and understand important and diverse types of therapeutics under development for Alopecia
    - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
    - Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Global Markets Direct Report Coverage 7
    Alopecia Overview 8
    Therapeutics Development 9
    Pipeline Products for Alopecia-Overview 9
    Pipeline Products for Alopecia-Comparative Analysis 10
    Alopecia-Therapeutics under Development by Companies 11
    Alopecia-Therapeutics under Investigation by Universities/Institutes 13
    Alopecia-Pipeline Products Glance 14
    Late Stage Products 14
    Clinical Stage Products 15
    Early Stage Products 16
    Alopecia-Products under Development by Companies 17
    Alopecia-Products under Investigation by Universities/Institutes 18
    Alopecia-Companies Involved in Therapeutics Development 19
    AndroScience Corporation 19
    Bristol-Myers Squibb Company 20
    C3 Jian, Inc 21
    Follicum AB 22
    Kuhnil Pharmaceutical Co., Ltd. 23
    Lee's Pharmaceutical Holdings Limited 24
    Panacea Biotec Limited 25
    ProCertus BioPharm Inc. 26
    Taisho Pharmaceutical Co., Ltd. 27
    Tigo GmbH 28
    Vida Therapeutics Inc. 29
    Alopecia-Therapeutics Assessment 30
    Assessment by Monotherapy Products 30
    Assessment by Target 31
    Assessment by Mechanism of Action 33
    Assessment by Route of Administration 35
    Assessment by Molecule Type 37
    Drug Profiles 39
    abatacept (recombinant)-Drug Profile 39
    Product Description 39
    Mechanism of Action 39
    R&D Progress 39
    ASCJ-9-Drug Profile 42
    Product Description 42
    Mechanism of Action 42
    R&D Progress 42
    calcitriol-Drug Profile 44
    Product Description 44
    Mechanism of Action 44
    R&D Progress 44
    DHL-HisZnNa-Drug Profile 45
    Product Description 45
    Mechanism of Action 45
    R&D Progress 45
    interferon beta-1b-Drug Profile 46
    Product Description 46
    Mechanism of Action 46
    R&D Progress 46
    KI-1104-Drug Profile 47
    Product Description 47
    Mechanism of Action 47
    R&D Progress 47
    KI-1105-Drug Profile 48
    Product Description 48
    Mechanism of Action 48
    R&D Progress 48
    Peptide for Alopecia-Drug Profile 49
    Product Description 49
    Mechanism of Action 49
    R&D Progress 49
    Peptide for Alopecia and Chemotherapy Effects-Drug Profile 50
    Product Description 50
    Mechanism of Action 50
    R&D Progress 50
    ProDermaCel-Drug Profile 52
    Product Description 52
    Mechanism of Action 52
    R&D Progress 52
    Recombinant Peptides for Alopecia-Drug Profile 53
    Product Description 53
    Mechanism of Action 53
    R&D Progress 53
    Recombinant Proteins to Antagonize IFN-Gamma Receptor for Alopecia Areata and Graft Arteriosclerosis-Drug Profile 54
    Product Description 54
    Mechanism of Action 54
    R&D Progress 54
    Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis-Drug Profile 55
    Product Description 55
    Mechanism of Action 55
    R&D Progress 55
    Small Molecules to Activate P2Y5 Receptor for Alopecia-Drug Profile 56
    Product Description 56
    Mechanism of Action 56
    R&D Progress 56
    Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia-Drug Profile 57
    Product Description 57
    Mechanism of Action 57
    R&D Progress 57
    V-2248-Drug Profile 58
    Product Description 58
    Mechanism of Action 58
    R&D Progress 58
    ZK-003-Drug Profile 59
    Product Description 59
    Mechanism of Action 59
    R&D Progress 59
    Alopecia-Recent Pipeline Updates 60
    Alopecia-Dormant Projects 63
    Alopecia-Discontinued Products 65
    Alopecia-Product Development Milestones 66
    Featured News & Press Releases 66
    Jul 23, 2012: Berg Pharma Launches Clinical Trial On BPM 31543 For Prevention Of Chemotherapy-induced Alopecia 66
    Appendix 67
    Methodology 67
    Coverage 67
    Secondary Research 67
    Primary Research 67
    Expert Panel Validation 67
    Contact Us 67
    Disclaimer 68

    List of Tables
    Number of Products under Development for Alopecia, H1 2015 9
    Number of Products under Development for Alopecia-Comparative Analysis, H1 2015 10
    Number of Products under Development by Companies, H1 2015 12
    Number of Products under Investigation by Universities/Institutes, H1 2015 13
    Comparative Analysis by Late Stage Development, H1 2015 14
    Comparative Analysis by Clinical Stage Development, H1 2015 15
    Comparative Analysis by Early Stage Development, H1 2015 16
    Products under Development by Companies, H1 2015 17
    Products under Investigation by Universities/Institutes, H1 2015 18
    Alopecia-Pipeline by AndroScience Corporation, H1 2015 19
    Alopecia-Pipeline by Bristol-Myers Squibb Company, H1 2015 20
    Alopecia-Pipeline by C3 Jian, Inc, H1 2015 21
    Alopecia-Pipeline by Follicum AB, H1 2015 22
    Alopecia-Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2015 23
    Alopecia-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 24
    Alopecia-Pipeline by Panacea Biotec Limited, H1 2015 25
    Alopecia-Pipeline by ProCertus BioPharm Inc., H1 2015 26
    Alopecia-Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 27
    Alopecia-Pipeline by Tigo GmbH, H1 2015 28
    Alopecia-Pipeline by Vida Therapeutics Inc., H1 2015 29
    Assessment by Monotherapy Products, H1 2015 30
    Number of Products by Stage and Target, H1 2015 32
    Number of Products by Stage and Mechanism of Action, H1 2015 34
    Number of Products by Stage and Route of Administration, H1 2015 36
    Number of Products by Stage and Molecule Type, H1 2015 38
    Alopecia Therapeutics-Recent Pipeline Updates, H1 2015 60
    Alopecia-Dormant Projects, H1 2015 63
    Alopecia-Dormant Projects (Contd..1), H1 2015 64
    Alopecia-Discontinued Products, H1 2015 65

    List of Figures
    Number of Products under Development for Alopecia, H1 2015 9
    Number of Products under Development for Alopecia-Comparative Analysis, H1 2015 10
    Number of Products under Development by Companies, H1 2015 11
    Number of Products under Investigation by Universities/Institutes, H1 2015 13
    Comparative Analysis by Clinical Stage Development, H1 2015 15
    Comparative Analysis by Early Stage Products, H1 2015 16
    Assessment by Monotherapy Products, H1 2015 30
    Number of Products by Top 10 Targets, H1 2015 31
    Number of Products by Stage and Top 10 Targets, H1 2015 32
    Number of Products by Top 10 Mechanism of Actions, H1 2015 33
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34
    Number of Products by Top 10 Routes of Administration, H1 2015 35
    Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36
    Number of Products by Top 10 Molecule Types, H1 2015 37
    Number of Products by Stage and Top 10 Molecule Types, H1 2015 38
    AndroScience Corporation
    Bristol-Myers Squibb Company
    C3 Jian, Inc
    Follicum AB
    Kuhnil Pharmaceutical Co., Ltd.
    Lee's Pharmaceutical Holdings Limited
    Panacea Biotec Limited
    ProCertus BioPharm Inc.
    Taisho Pharmaceutical Co., Ltd.
    Tigo GmbH
    Vida Therapeutics Inc.

    Request for Sample

    Report Url https://www.reportsweb.com//alopecia-pipeline-review-h1-2015&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//alopecia-pipeline-review-h1-2015&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//alopecia-pipeline-review-h1-2015&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments